

Part VI: Summary of the risk management plan

Summary of risk management plan for Allopurinol 100 mg, 300 mg tablets (Allopurinol)

This is a summary of the risk management plan (RMP) for Allopurinol 100 mg, 300 mg tablets. The RMP details important risks of Allopurinol 100 mg, 300 mg tablets, how these risks can be minimised, and how more information will be obtained about Allopurinol 100 mg, 300 mg tablet's risks and uncertainties (missing information).

Allopurinol 100 mg, 300 mg tablet's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Allopurinol 100 mg, 300 mg tablets should be used.

Important new concerns or changes to the current ones will be included in updates of Allopurinol 100 mg, 300 mg tablets RMP.

I. The medicine and what it is used for

Allopurinol 100 mg, 300 mg tablets is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy).

It contains Allopurinol as the active substance and it is given by oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Allopurinol 100 mg, 300 mg tablets, together with measures to minimise such risks and the proposed studies for learning more about Allopurinol 100 mg, 300 mg tablet's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment and signal management activity, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities. If important information that may affect the safe use of Allopurinol 100 mg, 300 mg tablets is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Allopurinol 100 mg, 300 mg tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Allopurinol 100 mg, 300 mg tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Important identified risks	Hypersensitivity reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis
Important potential risks	None
Missing information	Use in pregnant women

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Allopurinol 100 mg, 300 mg tablets.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Allopurinol 100 mg, 300 mg tablets.